Close
Smartlab Europe
Inizio Ignite

Press Releases

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, announced that the Philippine Food and Drug Administration...

Turkish Cargo participated in “Logitrans – 2021” fair

The global air cargo brand Turkish Cargo participated this year in Logitrans, Turkey's most extensive international transportation and logistics fair, for the 12th time. Having a 154 m2 wide stand area in the fair organized in CNR EXPO Istanbul Fair...

Syntegon enters strategic partnership with Bayer

Syntegon (formerly Bosch Packaging Technology), has entered a strategic partnershop with Bayer for the development of new continuous manufacturing processes for oral solid dosage (OSD) forms. The cooperation is based on the Xelum platform developed by the Syntegon subsidiary...

Roche’s Ronapreve approved by European Commission to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease

Roche announced that the European Commission has granted a marketing authorisation for Ronapreve™ (casirivimab and imdevimab), for treating COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) who do not require supplemental...

Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19

Regeneron Pharmaceuticals, Inc. announced that the EC has approved the casirivimab and imdevimab antibody cocktail, known as REGEN-COV® in the U.S. and Ronapreve™ in the European Union (EU) and other countries. The EC granted marketing authorization for the antibody...

AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025

AbbVie and the University of Chicago and have extended their collaboration agreement through 2025 to support preclinical oncology research. To date, the collaboration has led to novel insights related to biomarkers and therapeutic applications for existing AbbVie programs. This has...

Single Dose of Regen-Cov Provides Long-Term Protection Against COVID-19

Single dose of REGEN-COV (1,200 mg subcutaneous) reduced the risk of COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction previously reported during month 1 During the 8-month assessment period there were 0 hospitalizations...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »